# M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma

> **NCT00477906** · PHASE3 · UNKNOWN · sponsor: **AVAX Technologies** · enrollment: 387 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** M-Vax- autologous, hapten-modified melanoma vaccine

## Key facts

- **NCT ID:** NCT00477906
- **Lead sponsor:** AVAX Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2019-01
- **Final completion:** 2021-01
- **Target enrollment:** 387 (ESTIMATED)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00477906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00477906, "M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00477906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*